Brian J. Skaggs

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Neil P. Shah, Brian J. Skaggs, Susan Branford et al. · Journal of Clinical Investigation · 2007 · 415 citations · Full text

Medicine, Oncology, Pharmacology +13

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

Michael R. Burgess, Brian J. Skaggs, Neil P. Shah et al. · Proceedings of the National Academy of Sciences · 2005 · 312 citations

Medicine, Molecular Biology, Pharmacology +17

Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus

Maureen McMahon, Jennifer Grossman, Brian J. Skaggs et al. · Arthritis & Rheumatism · 2009 · 216 citations · Full text

Veterinary Medicine, Pathobiology, Inflammation +11

High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids

Maureen McMahon, Brian J. Skaggs, Lori Sahakian et al. · Annals of the Rheumatic Diseases · 2011 · 153 citations · Full text

Medicine, Endocrinology, Inflammation +14

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

Brian J. Skaggs, M. Gorre, Michael R. Burgess et al. · Proceedings of the National Academy of Sciences · 2006 · 146 citations

Medicine, Molecular Biology, Oncology +15